Seer, Inc. Class A Common Stock
SEERSeer, Inc. Class A (SEER) is a biotechnology company focused on developing advanced proteomics technologies to enable detailed analysis of proteins in biological samples. Its platform aims to facilitate breakthroughs in drug discovery, diagnostics, and research by providing high-throughput, precise, and scalable protein measurement solutions.
Company News
Seer presented multiple scientific studies at HUPO 2025, demonstrating how their Proteograph platform enables deep proteomics research across cardiovascular, aging, and cancer biology, showcasing the technology's potential for population-scale discovery and clinical translation.
The next-generation proteomics market is projected to expand rapidly between 2025-2034, driven by technological advancements, rising chronic disease prevalence, and increasing demand for personalized medicine across pharmaceutical, biotechnology, and diagnostic sectors.
Seer showcased how proteomics complements genomics in precision medicine research at the American Society of Human Genetics 2025 conference, presenting multiple scientific studies demonstrating the potential of their Proteograph Product Suite to uncover novel biomarkers and enhance disease understanding.
Seer, a life sciences technology firm, reported Q2 2025 revenue of $4.1 million, exceeding analyst expectations by 9.3% and representing a 32% year-over-year increase. Despite revenue growth, the company remains unprofitable with continued operating losses.
Seer, Inc. and Korea University are launching a large-scale proteomics study to identify biomarkers for early cancer detection in young adults, leveraging Seer's Proteograph platform and Thermo Scientific's Orbitrap Astral mass spectrometer.
